Abliva participates in World Mitochondrial Disease Week through videos that will be focused on increasing the understanding of the community to rare disease development, and more specifically to the development of new therapies for primary mitochondrial diseases. Over the week, we will highlight the important role patients have played in informing our strategy, discuss Abliva’s efforts to treat mitochondrial disease patients with our two clinical stage compounds, KL1333 and NV354, and hear from a patient, Daniela Gallo, about her struggles with the disease.
Starting 18 September, Abliva’s videos will be posted daily below.